ANGLE Reels In First Patient For Major US FDA Clinical Study
Executive Summary
ANGLE is moving closer to its goal of becoming the first ever company to receive US FDA clearance for a device that can harvest intact circulating tumor cells (CTCs) from patient blood for subsequent analysis.